Lansoprazole
- Generic Name
- Lansoprazole
- Brand Names
- Prevacid, Prevpac
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N3O2S
- CAS Number
- 103577-45-3
- Unique Ingredient Identifier
- 0K5C5T2QPG
- Background
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other patholog...
- Indication
Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of sever...
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis
- Associated Therapies
- -
Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT00637416
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients
- Conditions
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2008-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00625274
A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion
- Conditions
- Interventions
- First Posted Date
- 2007-10-18
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 16
- Registration Number
- NCT00546117
- Locations
- 🇺🇸
St. Louis Children's Hospital, Saint Louis, Missouri, United States
The Effects of Reducing Stomach Acid on Post-tonsillectomy Pain
- Conditions
- Interventions
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT00472186
- Locations
- 🇺🇸
Childrens Hospital Boston, Boston, Massachusetts, United States
🇺🇸Children's Hospital Boston, Boston, Massachusetts, United States
Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 831
- Registration Number
- NCT00471094
Pharmacokinetic Study of Lansoprazole in Cystic Fibrosis
- Conditions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Arkansas Children's Hospital Research Institute
- Target Recruit Count
- 18
- Registration Number
- NCT00458614
- Locations
- 🇺🇸
Arkansas Children's Hospital Little Rock, Little Rock, Arkansas, United States
Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?
- Conditions
- Interventions
- First Posted Date
- 2007-03-07
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 38
- Registration Number
- NCT00444145
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Endoscopy Lab, TVC 1410, Nashville, Tennessee, United States
Lansoprazole to Treat Children With Asthma
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 306
- Registration Number
- NCT00442013
- Locations
- 🇺🇸
University of Miami School of Medicine, Miami, Florida, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Washington University School of Medicine, St. Louis, Missouri, United States
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
- Conditions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 576
- Registration Number
- NCT00390390
- Locations
- 🇺🇸
Palm Beach Research, West Palm Beach, Florida, United States
🇺🇸Medical Edge Healthcare Group, Dallas, Texas, United States
🇺🇸Gaslamp Medical Center, San Diego, California, United States
Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux
- Conditions
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2012-08-24
- Lead Sponsor
- American Institute for Voice and Ear Research
- Target Recruit Count
- 18
- Registration Number
- NCT00369265
- Locations
- 🇺🇸
Henry Ford Hospital, Department of Otolaryngology, Detroit, Michigan, United States
🇺🇸American Institute for Voice and Ear Research, Philadelphia, Pennsylvania, United States
🇺🇸Cornell University, Van Lawrence Voice Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.